<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225354</url>
  </required_header>
  <id_info>
    <org_study_id>RAD-IMP-001</org_study_id>
    <nct_id>NCT01225354</nct_id>
  </id_info>
  <brief_title>Injectable Filler for Cheek Flattening</brief_title>
  <official_title>An Open-label, Prospective, Postmarket Study to Assess Altering First Impressions and Self-esteem Following Radiesse® Injections.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DeNova Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merz Aesthetics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DeNova Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Radiesse injections to the cheeks result in an
      altered and improved first impression and self esteem.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blinded Evaluations of First Impression</measure>
    <time_frame>After the 1-month post optimal correction visit for subject 20</time_frame>
    <description>Upon completion of the study, 300 blinded evaluators will evaluate one of three binders comprised of a random visit photographs from baseline, optimal cosmetic result, and 1 month post optimal cosmetic result of each of the 20 subjects. The 10-point (1=Not at all to 10=Extremely well) First Impression Scales consisting of 8 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-esteem</measure>
    <time_frame>1 month post-optimal cosmetic result</time_frame>
    <description>Self-esteem change will be determined by patient self-evaluation using the Heatherton &amp; Polivy State Self-Esteem (HPSS). The primary variable will be measured as improvement in self-esteem from baseline self-evaluations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-esteem</measure>
    <time_frame>2 weeks post optimal cosmetic result</time_frame>
    <description>Self-esteem change will be determined by patient self-evaluation using the Heatherton &amp; Polivy State Self-Esteem (HPSS). The primary variable will be measured as improvement in self-esteem from baseline self-evaluations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject First Impression</measure>
    <time_frame>baseline, Visit 2, Visit3, and Visit 4</time_frame>
    <description>Each subject will complete the 10-point (1-Not at all to 10-Very Much) evaluating their own first impression at Baseline, Visit 2 (if applicable), Visit 3, and Visit 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Malar Deficiency</measure>
    <time_frame>Visit 1-4</time_frame>
    <description>Live subject malar deficiency severity will be rated by PI at Visits 1-4 according to the SOBER scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aesthetic Improvement</measure>
    <time_frame>Visit 2-4</time_frame>
    <description>Subject and Investigator will complete GAIS at Visits 2-4 comparing overall appearance of current visit's photo to baseline photo</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Malar Deficiency</condition>
  <arm_group>
    <arm_group_label>Calcium hydroxylapatite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be treated at baseline and, if needed, at 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium hydroxylapatite</intervention_name>
    <description>Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.</description>
    <arm_group_label>Calcium hydroxylapatite</arm_group_label>
    <other_name>Radiesse</other_name>
    <other_name>CaHA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females between 30 and 65 years of age with Fitzpatrick Skin Color Types (I-VI).

          -  Have bilateral, fully visible aging defects in the malar area, corresponding to a
             rating of moderate to severe on the SOBER scale.

          -  Willingness and ability to comply with protocol requirements, including returning for
             follow-up visits and abstaining from exclusionary procedures for the duration of the
             study.

          -  Subjects of childbearing potential must have a negative urine pregnancy test result at
             Visit 1 and be willing able to use an acceptable method of birth control (e.g.,
             barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical
             sterilization, abstinence) during the study. Women will not be considered of
             childbearing potential if one of the following is documented on the medical history:

          -  postmenopausal for at least 12 months prior to study drug administration

          -  without a uterus and/or both ovaries

          -  has had a bilateral tubal ligation for at least 6 months prior to study drug
             administration.

          -  absence of an other physical condition according to the PI's discretion

          -  Willingness and ability to provide written photo consent and adherence to photography
             procedures (i.e., removal of jewelry and makeup).

          -  Willingness and ability to provide written informed consent prior to performance of
             any study related procedure.

        Exclusion Criteria:

          -  Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a
             reliable form of birth control.

          -  Subjects with a known allergy or sensitivity to any component of the study medications
             or anesthesia.

          -  Subjects who have had prior exposure to any calcium hydroxylapatite, or any other
             filler, injection for any purpose in the 12 months preceding study enrollment through
             the duration of the study (excluding study drug).

          -  Subjects who have had a prior cosmetic procedure to improve malar eminence deficiency
             (i.e., rhytidectomy, lower eyelid surgery, cheek implants, CO2/erbium laser
             resurfacing, Thermage/Thermacool radiofrequency treatment) or who have visible scars
             that may affect evaluation of response and/or quality of photography.

          -  Subjects who have had soft tissue augmentation of the malar area in the previous 6
             months.

          -  Permanent or semi-permanent dermal fillers in the malar area.

          -  Ablative skin resurfacing on the malar area within the previous 6 months or during the
             study.

          -  Retinoid, microdermabrasion, or prescription level glycolic acid treatments to the
             malar area within 2 weeks prior to study participation or during the study.

          -  Active infection in the malar area (e.g., acute acne lesions or ulcers).

          -  Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or
             thick sebaceous skin.

          -  Current history of chronic drug or alcohol abuse.

          -  History of autoimmune disease.

          -  Concurrent therapy that, in the investigator's opinion, would interfere with the
             evaluation of the safety or efficacy of the study medication.

          -  Subjects who anticipate the need for surgery or overnight hospitalization during the
             study.

          -  Subjects who, in the Investigator's opinion, have a history of poor cooperation,
             non¬compliance with medical treatment or unreliability.

          -  Enrollment in any active study involving the use of investigational devices or drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven H Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DeNova Research/ Chicago Center for Facial Plastic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.denovaresearch.com</url>
    <description>DeNova Research</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <results_first_submitted>August 29, 2012</results_first_submitted>
  <results_first_submitted_qc>August 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2012</results_first_posted>
  <last_update_submitted>September 27, 2012</last_update_submitted>
  <last_update_submitted_qc>September 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>DeNova Research</investigator_affiliation>
    <investigator_full_name>Steven H. Dayan</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>Cheek</keyword>
  <keyword>Cheek flattening</keyword>
  <keyword>Malar deficiency</keyword>
  <keyword>Filler</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Calcium Hydroxylapatite</title>
          <description>Subject will be treated at baseline and, if needed, at 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calcium Hydroxylapatite</title>
          <description>Subject will be treated at baseline and, if needed, at 2 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.2" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blinded Evaluations of First Impression</title>
        <description>Upon completion of the study, 300 blinded evaluators will evaluate one of three binders comprised of a random visit photographs from baseline, optimal cosmetic result, and 1 month post optimal cosmetic result of each of the 20 subjects. The 10-point (1=Not at all to 10=Extremely well) First Impression Scales consisting of 8 criteria.</description>
        <time_frame>After the 1-month post optimal correction visit for subject 20</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Self-esteem</title>
        <description>Self-esteem change will be determined by patient self-evaluation using the Heatherton &amp; Polivy State Self-Esteem (HPSS). The primary variable will be measured as improvement in self-esteem from baseline self-evaluations.</description>
        <time_frame>1 month post-optimal cosmetic result</time_frame>
        <population>All subjects completing indicated visit</population>
        <group_list>
          <group group_id="O1">
            <title>Calcium Hydroxylapatite</title>
            <description>Subject will be treated at baseline and, if needed, at 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-esteem</title>
          <description>Self-esteem change will be determined by patient self-evaluation using the Heatherton &amp; Polivy State Self-Esteem (HPSS). The primary variable will be measured as improvement in self-esteem from baseline self-evaluations.</description>
          <population>All subjects completing indicated visit</population>
          <units>Participants with improved self-esteem</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="12.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Self-esteem</title>
        <description>Self-esteem change will be determined by patient self-evaluation using the Heatherton &amp; Polivy State Self-Esteem (HPSS). The primary variable will be measured as improvement in self-esteem from baseline self-evaluations.</description>
        <time_frame>2 weeks post optimal cosmetic result</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcium Hydroxylapatite</title>
            <description>Subject will be treated at baseline and, if needed, at 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-esteem</title>
          <description>Self-esteem change will be determined by patient self-evaluation using the Heatherton &amp; Polivy State Self-Esteem (HPSS). The primary variable will be measured as improvement in self-esteem from baseline self-evaluations.</description>
          <units>Participants with improved self-esteem</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" spread="11.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject First Impression</title>
        <description>Each subject will complete the 10-point (1-Not at all to 10-Very Much) evaluating their own first impression at Baseline, Visit 2 (if applicable), Visit 3, and Visit 4.</description>
        <time_frame>baseline, Visit 2, Visit3, and Visit 4</time_frame>
        <posting_date>12/2013</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Malar Deficiency</title>
        <description>Live subject malar deficiency severity will be rated by PI at Visits 1-4 according to the SOBER scale.</description>
        <time_frame>Visit 1-4</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aesthetic Improvement</title>
        <description>Subject and Investigator will complete GAIS at Visits 2-4 comparing overall appearance of current visit’s photo to baseline photo</description>
        <time_frame>Visit 2-4</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Calcium Hydroxylapatite</title>
          <description>Subject will be treated at baseline and, if needed, at 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jack Arkins, Data Manager</name_or_title>
      <organization>DeNova Research</organization>
      <phone>312-335-2070</phone>
      <email>jack@drdayan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

